Cantor Fitzgerald tells investors after Viking Therapeutics (VKTX)’ “transformative” Q3 update that “this was the most bullish update Viking has given since we started covering the stock more than 7 years ago.” Viking “just crystallized five critically important data catalysts in the next 24 months” and the company affirmed cash on hand of greater than $700M was sufficient to get through all of them, according to the analyst, who has an Overweight rating and $105 price target on Viking shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VKTX:
- Viking Therapeutics Advances Obesity Treatment Pipeline
- Viking Therapeutics Gains Buy Rating Amid Promising Obesity Treatment Developments and Strategic Advancements
- Viking Therapeutics reports Q3 EPS (81c), consensus (67c)
- Viking Therapeutics options imply 7.6% move in share price post-earnings
- Options Volatility and Implied Earnings Moves Today, October 22, 2025